These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31647573)

  • 1. Therapeutic targets in myeloma bone disease.
    Marino S; Petrusca DN; Roodman GD
    Br J Pharmacol; 2021 May; 178(9):1907-1922. PubMed ID: 31647573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Myeloma Bone Lesions.
    Du JS; Yen CH; Hsu CM; Hsiao HH
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
    Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New agents in the Treatment of Myeloma Bone Disease.
    Ring ES; Lawson MA; Snowden JA; Jolley I; Chantry AD
    Calcif Tissue Int; 2018 Feb; 102(2):196-209. PubMed ID: 29098361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for delivering drugs to bone.
    Sun S; Tao J; Sedghizadeh PP; Cherian P; Junka AF; Sodagar E; Xing L; Boeckman RK; Srinivasan V; Yao Z; Boyce BF; Lipe B; Neighbors JD; Russell RGG; McKenna CE; Ebetino FH
    Br J Pharmacol; 2021 May; 178(9):2008-2025. PubMed ID: 32876338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
    Lee OL; Horvath N; Lee C; Joshua D; Ho J; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Talaulikar D; Brown R; Augustson B; Ling S; Jaksic W; Gibson J; Kalff A; Johnston A; Kalro A; Ward C; Prince HM; Zannettino A
    Intern Med J; 2017 Aug; 47(8):938-951. PubMed ID: 28782211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic targets in myeloma bone disease.
    Webb SL; Edwards CM
    Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bone-modifying agents in myeloma bone disease.
    Lu H; Pundole X; Lee HC
    JBMR Plus; 2021 Aug; 5(8):e10518. PubMed ID: 34368608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of treatment approaches to osteoporosis.
    Langdahl BL
    Br J Pharmacol; 2021 May; 178(9):1891-1906. PubMed ID: 32060897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-coding RNAs in bone remodelling and bone metastasis: Mechanisms of action and translational relevance.
    Puppo M; Taipaleenmäki H; Hesse E; Clézardin P
    Br J Pharmacol; 2021 May; 178(9):1936-1954. PubMed ID: 31423566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible targets to treat myeloma-related osteoclastogenesis.
    Bolzoni M; Toscani D; Storti P; Marchica V; Costa F; Giuliani N
    Expert Rev Hematol; 2018 Apr; 11(4):325-336. PubMed ID: 29495905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Evidence-Based Approach to Myeloma Bone Disease.
    Bingham N; Reale A; Spencer A
    Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of bisphosphonates in pain.
    Tzschentke TM
    Br J Pharmacol; 2021 May; 178(9):1973-1994. PubMed ID: 31347149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of myeloma bone disease.
    Esteve FR; Roodman GD
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):613-24. PubMed ID: 18070709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloma bone disease: pathogenesis and treatment.
    O'Donnell EK; Raje NS
    Clin Adv Hematol Oncol; 2017 Apr; 15(4):285-295. PubMed ID: 28591104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology and treatment of myeloma related bone disease.
    Terpos E; Christoulas D; Gavriatopoulou M
    Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloma and Bone Disease.
    Panaroni C; Yee AJ; Raje NS
    Curr Osteoporos Rep; 2017 Oct; 15(5):483-498. PubMed ID: 28861842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.
    Pennisi A; Ling W; Li X; Khan S; Wang Y; Barlogie B; Shaughnessy JD; Yaccoby S
    PLoS One; 2010 Dec; 5(12):e15233. PubMed ID: 21188144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic options in the management of myeloma bone disease.
    Berenson JR
    Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.